beta

ADMS

Adamas Pharmaceuticals, Inc.

Adms

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.

Market Cap: 180 Million

Primary Exchange: NASDAQ

Website: http://www.adamaspharma.com

Shares Outstanding: 27.9 Million

Float: 22.2 Million

Dividend: (%)

Beta: 1.21375220713257

Sector: Health Technology

Industry: Pharmaceuticals: Other

Ethical Flags

Animal testing

Longest drawdown: 489 trading days

From: 2018-01-23 To: 2019-12-06

Lowest Point:

ADMS INVESTORS ALERT: Lieff Cabraser Announces Securities Class Action Against Adamas Pharmaceuticals, Inc.

via: Business Wire at 2019-06-10 05:00:00:000

The law firm of Lieff Cabraser Heimann & Bernstein, LLP announces that class action litigation has been filed on behalf of investors who purchased the common stock of Adamas Pharmaceuticals, Inc. (Adamas or the Company) (Nasdaq: ADMS) directly in the Com… read more...

ADMS INVESTORS ALERT: Lieff Cabraser Announces Securities Class Action Against Adamas Pharmaceuticals, Inc.

via: Business Wire at 2019-06-10 05:00:00:000

The law firm of Lieff Cabraser Heimann & Bernstein, LLP announces that class action litigation has been filed on behalf of investors who purchased the common stock of Adamas Pharmaceuticals, Inc. (Adamas or the Company) (Nasdaq: ADMS) directly in the Com… read more...

ADMS INVESTORS ALERT: Lieff Cabraser Announces Securities Class Action Against Adamas Pharmaceuticals, Inc.

via: Business Wire at 2019-06-10 05:00:00:000

The law firm of Lieff Cabraser Heimann & Bernstein, LLP announces that class action litigation has been filed on behalf of investors who purchased the common stock of Adamas Pharmaceuticals, Inc. (Adamas or the Company) (Nasdaq: ADMS) directly in the Com… read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud